Literature DB >> 19030518

Long-acting stimulants: development and dosing.

James M Swanson1.   

Abstract

Year:  2005        PMID： 19030518      PMCID： PMC2547091     

Source DB:  PubMed          Journal:  Can Child Adolesc Psychiatr Rev        ISSN： 1716-9119


× No keyword cloud information.
  11 in total

Review 1.  Serum and brain concentrations of methylphenidate: implications for use and abuse.

Authors:  J M Swanson; N D Volkow
Journal:  Neurosci Biobehav Rev       Date:  2003-11       Impact factor: 8.989

2.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

3.  Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

4.  Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Authors:  W E Pelham; E M Gnagy; L Burrows-Maclean; A Williams; G A Fabiano; S M Morrisey; A M Chronis; G L Forehand; C A Nguyen; M T Hoffman; T M Lock; K Fielbelkorn; E K Coles; C J Panahon; R L Steiner; D L Meichenbaum; A N Onyango; G D Morse
Journal:  Pediatrics       Date:  2001-06       Impact factor: 7.124

5.  Evaluation of individual subjects in the analog classroom setting: I. Examples of graphical and statistical procedures for within-subject ranking of responses to different delivery patterns of methylphenidate.

Authors:  J M Swanson; S B Wigal; D Udrea; M Lerner; D Agler; D Flynn; E Fineberg; M Davies; D Kardatzke; A Ram; S Gupta
Journal:  Psychopharmacol Bull       Date:  1998

6.  ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.

Authors:  Timothy Wilens; William Pelham; Mark Stein; C Keith Conners; Howard Abikoff; Marc Atkins; Gerald August; Laurence Greenhill; Keith McBurnett; Donna Palumbo; James Swanson; Mark Wolraich
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-04       Impact factor: 8.829

7.  Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.

Authors:  James Swanson; Suneel Gupta; Andrew Lam; Ira Shoulson; Marc Lerner; Nishit Modi; Elizabeth Lindemulder; Sharon Wigal
Journal:  Arch Gen Psychiatry       Date:  2003-02

8.  A pharmacokinetic/pharmacodynamic study comparing a single morning dose of adderall to twice-daily dosing in children with ADHD.

Authors:  Laurence L Greenhill; James M Swanson; Ken Steinhoff; Jane Fried; Kelly Posner; Marc Lerner; Sharon Wigal; Susan B Clausen; Yuxin Zhang; Simon Tulloch
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-10       Impact factor: 8.829

9.  Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall.

Authors:  James J McGough; Joseph Biederman; Laurence L Greenhill; James T McCracken; Thomas J Spencer; Kelly Posner; Sharon Wigal; Jeffrey Gornbein; Simon Tulloch; James M Swanson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-06       Impact factor: 8.829

10.  Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.

Authors:  James T McCracken; Joseph Biederman; Laurence L Greenhill; James M Swanson; James J McGough; Thomas J Spencer; Kelly Posner; Sharon Wigal; Caroly Pataki; Yuxin Zhang; Simon Tulloch
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-06       Impact factor: 8.829
View more
  3 in total

Review 1.  Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy.

Authors:  James C Ermer; Michael Pennick; Glen Frick
Journal:  Clin Drug Investig       Date:  2016-05       Impact factor: 2.859

2.  Randomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults.

Authors:  Martin A Katzman; Greg Mattingly; Larry J Klassen; Marc J Cataldo; Graeme A E Donnelly
Journal:  J Clin Psychopharmacol       Date:  2020 Nov/Dec       Impact factor: 3.118

3.  Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHD.

Authors:  Ann Childress; Andrew J Cutler; Andrea H Marraffino; Sailaja Bhaskar; Graeme Donnelly
Journal:  J Atten Disord       Date:  2021-06-30       Impact factor: 3.256
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.